Cocrystal Pharma Provides Update on Influenza A Program
19. Oktober 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...